Shawky Michael S, Ricciardelli Carmela, Lord Megan, Whitelock John, Ferro Vito, Britt Kara, Thompson Erik W
J Mammary Gland Biol Neoplasia. 2015 Dec;20(3-4):121-31. doi: 10.1007/s10911-015-9346-z.
Although increased mammographic density (MD) has been well established as a marker for increased breast cancer (BC) risk, its pathobiology is far from understood. Altered proteoglycan (PG) composition may underpin the physical properties of MD, and may contribute to the associated increase in BC risk. Numerous studies have investigated PGs, which are a major stromal matrix component, in relation to MD and BC and reported results that are sometimes discordant. Our review summarises these results and highlights discrepancies between PG associations with BC and MD, thus serving as a guide for identifying PGs that warrant further research towards developing chemo-preventive or therapeutic agents targeting preinvasive or invasive breast lesions, respectively.
尽管乳腺钼靶密度（MD）增加已被明确确立为乳腺癌（BC）风险增加的标志物，但其病理生物学仍远未被理解。蛋白聚糖（PG）组成的改变可能是MD物理特性的基础，并可能导致BC风险的相应增加。许多研究已经调查了作为主要基质成分的PG与MD和BC的关系，并报告了有时不一致的结果。我们的综述总结了这些结果，并强调了PG与BC和MD之间关联的差异，从而为识别PG提供指导，这些PG分别值得进一步研究以开发针对乳腺原位癌或浸润性乳腺病变的化学预防或治疗药物。
